RU2008112221A - Соединения ряда изоиндолимидов, их композиции и способы применения - Google Patents
Соединения ряда изоиндолимидов, их композиции и способы применения Download PDFInfo
- Publication number
- RU2008112221A RU2008112221A RU2008112221/04A RU2008112221A RU2008112221A RU 2008112221 A RU2008112221 A RU 2008112221A RU 2008112221/04 A RU2008112221/04 A RU 2008112221/04A RU 2008112221 A RU2008112221 A RU 2008112221A RU 2008112221 A RU2008112221 A RU 2008112221A
- Authority
- RU
- Russia
- Prior art keywords
- dioxopiperidin
- isoindol
- dihydro
- ylmethyl
- dioxo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 41
- 238000000034 method Methods 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title claims 2
- 150000003839 salts Chemical class 0.000 claims abstract 33
- 239000012453 solvate Substances 0.000 claims abstract 32
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract 26
- 229910052736 halogen Inorganic materials 0.000 claims abstract 19
- 150000002367 halogens Chemical group 0.000 claims abstract 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims abstract 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 3
- 125000005843 halogen group Chemical group 0.000 claims abstract 3
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims abstract 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 2
- PKPFTQJXZQDMCJ-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(3-hydroxy-4-methoxyanilino)isoindole-1,3-dione Chemical compound C1=C(O)C(OC)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O PKPFTQJXZQDMCJ-UHFFFAOYSA-N 0.000 claims description 2
- MFTGPBBTIJJBRR-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-[4-(2-morpholin-4-ylethoxy)anilino]isoindole-1,3-dione Chemical compound O=C1C(C(=CC=C2)NC=3C=CC(OCCN4CCOCC4)=CC=3)=C2C(=O)N1C1CCC(=O)NC1=O MFTGPBBTIJJBRR-UHFFFAOYSA-N 0.000 claims description 2
- WJXROABCSGSUHM-UHFFFAOYSA-N 3,4-dichloro-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]benzamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O WJXROABCSGSUHM-UHFFFAOYSA-N 0.000 claims description 2
- FMSAGEBGPVOGMC-UHFFFAOYSA-N 4-[4-[2-(dimethylamino)ethoxy]-2-methoxyanilino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound COC1=CC(OCCN(C)C)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O FMSAGEBGPVOGMC-UHFFFAOYSA-N 0.000 claims description 2
- QVDCYXUXNJDAEB-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3,4-difluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O QVDCYXUXNJDAEB-UHFFFAOYSA-N 0.000 claims description 2
- -1 [2- (2,6-dioxopiperidin-3-yl) -1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl] furan-2-carboxylic acid amide Chemical compound 0.000 claims 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000006529 (C3-C6) alkyl group Chemical group 0.000 claims 2
- BOGDMPVDCOPYTP-UHFFFAOYSA-N 2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]-n-methylacetamide Chemical compound O=C1C=2C(NCC(=O)NC)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O BOGDMPVDCOPYTP-UHFFFAOYSA-N 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- JTRZLJRTWPSEMO-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-thiophen-2-ylacetamide Chemical compound C=1C=CC=2C(=O)N(C3C(NC(=O)CC3)=O)C(=O)C=2C=1CNC(=O)CC1=CC=CS1 JTRZLJRTWPSEMO-UHFFFAOYSA-N 0.000 claims 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical group N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 2
- 229930192474 thiophene Natural products 0.000 claims 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- DBEDILYRSLIYIW-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]urea Chemical compound C=1C=C2OCOC2=CC=1NC(=O)NCC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O DBEDILYRSLIYIW-UHFFFAOYSA-N 0.000 claims 1
- WZCFLLDUFVTHEH-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]urea Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O WZCFLLDUFVTHEH-UHFFFAOYSA-N 0.000 claims 1
- KFNLIHFPFQAZBA-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]urea Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)NCC1=CC=CC2=C1CN(C1C(NC(=O)CC1)=O)C2=O KFNLIHFPFQAZBA-UHFFFAOYSA-N 0.000 claims 1
- LEJTYTWAJQOBLI-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]urea Chemical compound C1=C(C)C(C)=CC=C1NC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O LEJTYTWAJQOBLI-UHFFFAOYSA-N 0.000 claims 1
- MPXNILDVBMGMLE-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]urea Chemical compound C1=C(C)C(C)=CC=C1NC(=O)NCC1=CC=CC2=C1CN(C1C(NC(=O)CC1)=O)C2=O MPXNILDVBMGMLE-UHFFFAOYSA-N 0.000 claims 1
- IMRZNKKFBJZQLI-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]urea Chemical compound C1=C(Cl)C(C)=CC=C1NC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O IMRZNKKFBJZQLI-UHFFFAOYSA-N 0.000 claims 1
- QDHHVGHQYFUSIF-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]urea Chemical compound C1=C(Cl)C(C)=CC=C1NC(=O)NCC1=CC=CC2=C1CN(C1C(NC(=O)CC1)=O)C2=O QDHHVGHQYFUSIF-UHFFFAOYSA-N 0.000 claims 1
- HUDNPKXYGKFYNW-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]urea Chemical compound ClC1=CC=CC(NC(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 HUDNPKXYGKFYNW-UHFFFAOYSA-N 0.000 claims 1
- NQWIUPXEQAAVLK-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]urea Chemical compound ClC1=CC=CC(NC(=O)NCC=2C=3CN(C(=O)C=3C=CC=2)C2C(NC(=O)CC2)=O)=C1 NQWIUPXEQAAVLK-UHFFFAOYSA-N 0.000 claims 1
- CZBATVKQYBXGJG-UHFFFAOYSA-N 1-(3-cyanophenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]urea Chemical compound C=1C=CC(C#N)=CC=1NC(=O)NCC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O CZBATVKQYBXGJG-UHFFFAOYSA-N 0.000 claims 1
- QXECHPGBLXNRFW-UHFFFAOYSA-N 1-(3-cyanophenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]urea Chemical compound C=1C=CC(C#N)=CC=1NC(=O)NCC(C=1C2)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O QXECHPGBLXNRFW-UHFFFAOYSA-N 0.000 claims 1
- NDZFTGPJNFRMGE-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NCC1=CC=CC2=C1CN(C1C(NC(=O)CC1)=O)C2=O NDZFTGPJNFRMGE-UHFFFAOYSA-N 0.000 claims 1
- IRGUABXSFDEVAP-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-(2-methoxyphenyl)urea Chemical compound COC1=CC=CC=C1NC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O IRGUABXSFDEVAP-UHFFFAOYSA-N 0.000 claims 1
- JTBYOUYITAKJNB-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-(2-methylphenyl)urea Chemical compound CC1=CC=CC=C1NC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O JTBYOUYITAKJNB-UHFFFAOYSA-N 0.000 claims 1
- GUIOIELEBCCIGK-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-(3-methoxyphenyl)urea Chemical compound COC1=CC=CC(NC(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 GUIOIELEBCCIGK-UHFFFAOYSA-N 0.000 claims 1
- COLOKVUIVSZCDK-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 COLOKVUIVSZCDK-UHFFFAOYSA-N 0.000 claims 1
- CYLKLJIJQCOIOV-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-(4-methoxyphenyl)urea Chemical compound C1=CC(OC)=CC=C1NC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O CYLKLJIJQCOIOV-UHFFFAOYSA-N 0.000 claims 1
- DNTBNFJUYZGVFN-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-(4-methylphenyl)urea Chemical compound C1=CC(C)=CC=C1NC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O DNTBNFJUYZGVFN-UHFFFAOYSA-N 0.000 claims 1
- GLMYXOWULMTADC-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-naphthalen-1-ylurea Chemical compound C=1C=CC2=CC=CC=C2C=1NC(=O)NCC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O GLMYXOWULMTADC-UHFFFAOYSA-N 0.000 claims 1
- LPYSLVJAVQDUHX-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-naphthalen-2-ylurea Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)NCC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O LPYSLVJAVQDUHX-UHFFFAOYSA-N 0.000 claims 1
- LSOUTIBZIHOBDA-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-pyridin-2-ylurea Chemical compound C=1C=CC=NC=1NC(=O)NCC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O LSOUTIBZIHOBDA-UHFFFAOYSA-N 0.000 claims 1
- CXHNAOZWAIXLHQ-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-3-(2-methoxyphenyl)urea Chemical compound COC1=CC=CC=C1NC(=O)NCC1=CC=CC2=C1CN(C1C(NC(=O)CC1)=O)C2=O CXHNAOZWAIXLHQ-UHFFFAOYSA-N 0.000 claims 1
- PXFDDGACHUAIPS-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-3-(3-methoxyphenyl)urea Chemical compound COC1=CC=CC(NC(=O)NCC=2C=3CN(C(=O)C=3C=CC=2)C2C(NC(=O)CC2)=O)=C1 PXFDDGACHUAIPS-UHFFFAOYSA-N 0.000 claims 1
- CMISAXSRPDDAFW-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-3-(4-methoxyphenyl)urea Chemical compound C1=CC(OC)=CC=C1NC(=O)NCC1=CC=CC2=C1CN(C1C(NC(=O)CC1)=O)C2=O CMISAXSRPDDAFW-UHFFFAOYSA-N 0.000 claims 1
- CHXJENCPRXMXSA-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-3-naphthalen-1-ylurea Chemical compound C=1C=CC2=CC=CC=C2C=1NC(=O)NCC(C=1C2)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O CHXJENCPRXMXSA-UHFFFAOYSA-N 0.000 claims 1
- ZINYZHJJCWLLPR-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-3-naphthalen-2-ylurea Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)NCC(C=1C2)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O ZINYZHJJCWLLPR-UHFFFAOYSA-N 0.000 claims 1
- MPFAPXMBTNMGFS-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-3-phenylurea Chemical compound C=1C=CC=CC=1NC(=O)NCC(C=1C2)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O MPFAPXMBTNMGFS-UHFFFAOYSA-N 0.000 claims 1
- DTKADAOJXGQQKX-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-3-propylurea Chemical compound C1C=2C(CNC(=O)NCCC)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O DTKADAOJXGQQKX-UHFFFAOYSA-N 0.000 claims 1
- KJZUNTFZLZQYOE-UHFFFAOYSA-N 1-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-3-pyridin-3-ylurea Chemical compound C=1C=CN=CC=1NC(=O)NCC(C=1C2)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O KJZUNTFZLZQYOE-UHFFFAOYSA-N 0.000 claims 1
- LPYNIXUWYVYZOW-UHFFFAOYSA-N 1-benzyl-3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]urea Chemical compound C=1C=CC=2C(=O)N(C3C(NC(=O)CC3)=O)CC=2C=1CNC(=O)NCC1=CC=CC=C1 LPYNIXUWYVYZOW-UHFFFAOYSA-N 0.000 claims 1
- AQRVRELWUJJSAG-UHFFFAOYSA-N 1-cyclohexyl-3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]thiourea Chemical compound O=C1N(C2C(NC(=O)CC2)=O)CC2=C1C=CC=C2CNC(=S)NC1CCCCC1 AQRVRELWUJJSAG-UHFFFAOYSA-N 0.000 claims 1
- FKSWKJPUVVSJFZ-UHFFFAOYSA-N 1-cyclohexyl-3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]urea Chemical compound C1CCCCC1NC(=O)NCC(C=1C2)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O FKSWKJPUVVSJFZ-UHFFFAOYSA-N 0.000 claims 1
- JPZQLTSRYXXVQS-UHFFFAOYSA-N 1-ethyl-3-[[2-(3-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]urea Chemical compound O=C1C=2C(CNC(=O)NCC)=CC=CC=2C(=O)N1C1(C)CCC(=O)NC1=O JPZQLTSRYXXVQS-UHFFFAOYSA-N 0.000 claims 1
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical compound C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 claims 1
- BYRUVXQNSXJUJZ-UHFFFAOYSA-N 2-(2,5-dimethyl-1,3-thiazol-4-yl)-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound S1C(C)=NC(CC(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1C BYRUVXQNSXJUJZ-UHFFFAOYSA-N 0.000 claims 1
- CUDVEJXHGIXXOY-UHFFFAOYSA-N 2-(2,5-dimethylfuran-3-yl)-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound O1C(C)=CC(CC(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1C CUDVEJXHGIXXOY-UHFFFAOYSA-N 0.000 claims 1
- SXLYKJMWADRDAY-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(1-methoxypropan-2-ylamino)isoindole-1,3-dione Chemical compound O=C1C=2C(NC(C)COC)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O SXLYKJMWADRDAY-UHFFFAOYSA-N 0.000 claims 1
- IOXASHGLQAZTEW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(2-methoxyanilino)isoindole-1,3-dione Chemical compound COC1=CC=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O IOXASHGLQAZTEW-UHFFFAOYSA-N 0.000 claims 1
- AJYRCMQAFQIXPW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(2-phenoxyanilino)isoindole-1,3-dione Chemical compound O=C1C(C(=CC=C2)NC=3C(=CC=CC=3)OC=3C=CC=CC=3)=C2C(=O)N1C1CCC(=O)NC1=O AJYRCMQAFQIXPW-UHFFFAOYSA-N 0.000 claims 1
- SUMYYYWWZRSYJQ-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(3-ethoxy-4-methoxyanilino)isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(NC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 SUMYYYWWZRSYJQ-UHFFFAOYSA-N 0.000 claims 1
- XRDUMBOYKDHGSQ-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(3-methoxyanilino)isoindole-1,3-dione Chemical compound COC1=CC=CC(NC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 XRDUMBOYKDHGSQ-UHFFFAOYSA-N 0.000 claims 1
- ROZDJTGGCVSITH-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(4-methoxy-2-phenoxyanilino)isoindole-1,3-dione Chemical compound C=1C=CC=CC=1OC1=CC(OC)=CC=C1NC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O ROZDJTGGCVSITH-UHFFFAOYSA-N 0.000 claims 1
- BWMPFRQENZHKOO-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(4-propan-2-ylanilino)isoindole-1,3-dione Chemical compound C1=CC(C(C)C)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O BWMPFRQENZHKOO-UHFFFAOYSA-N 0.000 claims 1
- DIXZOJXRSQZYFS-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(naphthalen-2-ylamino)isoindole-1,3-dione Chemical compound O=C1C(C(=CC=C2)NC=3C=C4C=CC=CC4=CC=3)=C2C(=O)N1C1CCC(=O)NC1=O DIXZOJXRSQZYFS-UHFFFAOYSA-N 0.000 claims 1
- RZRKVIIGOZYNJI-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(pyridin-2-ylmethylamino)isoindole-1,3-dione;hydrochloride Chemical compound Cl.O=C1C(C(=CC=C2)NCC=3N=CC=CC=3)=C2C(=O)N1C1CCC(=O)NC1=O RZRKVIIGOZYNJI-UHFFFAOYSA-N 0.000 claims 1
- SQUBDULHAAWZJP-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(pyridin-4-ylmethylamino)isoindole-1,3-dione;hydrochloride Chemical compound Cl.O=C1C(C(=CC=C2)NCC=3C=CN=CC=3)=C2C(=O)N1C1CCC(=O)NC1=O SQUBDULHAAWZJP-UHFFFAOYSA-N 0.000 claims 1
- CQVZIWBGMCEMQW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-[2-fluoro-4-(2-morpholin-4-ylethoxy)anilino]isoindole-1,3-dione Chemical compound C=1C=C(NC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)C(F)=CC=1OCCN1CCOCC1 CQVZIWBGMCEMQW-UHFFFAOYSA-N 0.000 claims 1
- BXZNWCRQTHBZQG-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-[2-methoxy-4-(2-morpholin-4-ylethoxy)anilino]isoindole-1,3-dione;hydrochloride Chemical compound Cl.C=1C=C(NC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)C(OC)=CC=1OCCN1CCOCC1 BXZNWCRQTHBZQG-UHFFFAOYSA-N 0.000 claims 1
- OTGVBMANDTXTSP-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-[2-methoxy-4-(2-piperidin-1-ylethoxy)anilino]isoindole-1,3-dione Chemical compound C=1C=C(NC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)C(OC)=CC=1OCCN1CCCCC1 OTGVBMANDTXTSP-UHFFFAOYSA-N 0.000 claims 1
- BMDCTBDGVVTCRL-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-[2-methoxy-4-(2-pyrrolidin-1-ylethoxy)anilino]isoindole-1,3-dione Chemical compound C=1C=C(NC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)C(OC)=CC=1OCCN1CCCC1 BMDCTBDGVVTCRL-UHFFFAOYSA-N 0.000 claims 1
- KPYUVWANUCMXGX-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-[3-(2-morpholin-4-ylethoxy)anilino]isoindole-1,3-dione Chemical compound O=C1C(C(=CC=C2)NC=3C=C(OCCN4CCOCC4)C=CC=3)=C2C(=O)N1C1CCC(=O)NC1=O KPYUVWANUCMXGX-UHFFFAOYSA-N 0.000 claims 1
- UBGOXMVVLLPBNS-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O UBGOXMVVLLPBNS-UHFFFAOYSA-N 0.000 claims 1
- VEVPRGNAQVWEAN-UHFFFAOYSA-N 2-(3,5-difluorophenyl)-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound FC1=CC(F)=CC(CC(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 VEVPRGNAQVWEAN-UHFFFAOYSA-N 0.000 claims 1
- QZVVTNWOCZYLOQ-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound COC1=CC(OC)=CC(CC(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 QZVVTNWOCZYLOQ-UHFFFAOYSA-N 0.000 claims 1
- NSDLCBLFTBIABG-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound ClC1=CC=CC(CC(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 NSDLCBLFTBIABG-UHFFFAOYSA-N 0.000 claims 1
- KFTAFQYGSWDRBP-UHFFFAOYSA-N 2-(3-methyl-2,6-dioxopiperidin-3-yl)-4-(pentylamino)isoindole-1,3-dione Chemical compound O=C1C=2C(NCCCCC)=CC=CC=2C(=O)N1C1(C)CCC(=O)NC1=O KFTAFQYGSWDRBP-UHFFFAOYSA-N 0.000 claims 1
- VCDURLLLANWRFJ-UHFFFAOYSA-N 2-(4,5-dimethylfuran-2-yl)-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound O1C(C)=C(C)C=C1CC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O VCDURLLLANWRFJ-UHFFFAOYSA-N 0.000 claims 1
- YLAJZSXJEZECSL-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound C1=CC(Cl)=CC=C1CC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O YLAJZSXJEZECSL-UHFFFAOYSA-N 0.000 claims 1
- GEWYYKFLGPGQPD-UHFFFAOYSA-N 2-(dimethylamino)-n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]acetamide;hydrochloride Chemical compound Cl.C1C=2C(CNC(=O)CN(C)C)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GEWYYKFLGPGQPD-UHFFFAOYSA-N 0.000 claims 1
- VLEZWPFWQVUVAM-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CC(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 VLEZWPFWQVUVAM-UHFFFAOYSA-N 0.000 claims 1
- UFCZPVXJGAFOQS-UHFFFAOYSA-N 2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]-n-phenylacetamide Chemical compound C=1C=CC=CC=1NC(=O)CNC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O UFCZPVXJGAFOQS-UHFFFAOYSA-N 0.000 claims 1
- LRGLFYOYKPSPJQ-UHFFFAOYSA-N 2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]acetic acid Chemical compound O=C1C=2C(NCC(=O)O)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O LRGLFYOYKPSPJQ-UHFFFAOYSA-N 0.000 claims 1
- VCBFVJBQFJLBQS-UHFFFAOYSA-N 2-chloro-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]benzamide Chemical compound ClC1=CC=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O VCBFVJBQFJLBQS-UHFFFAOYSA-N 0.000 claims 1
- NBBHXJAALPXFGD-UHFFFAOYSA-N 3,4-dichloro-n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]benzamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)NCC1=CC=CC2=C1CN(C1C(NC(=O)CC1)=O)C2=O NBBHXJAALPXFGD-UHFFFAOYSA-N 0.000 claims 1
- JJJFVSUNYBHUGJ-UHFFFAOYSA-N 3,5-dichloro-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]benzamide Chemical compound ClC1=CC(Cl)=CC(C(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 JJJFVSUNYBHUGJ-UHFFFAOYSA-N 0.000 claims 1
- FGHAIGPZKUTUSD-UHFFFAOYSA-N 3-(difluoromethoxy)-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]benzamide Chemical compound FC(F)OC1=CC=CC(C(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 FGHAIGPZKUTUSD-UHFFFAOYSA-N 0.000 claims 1
- UZHODHVYNPJSAE-UHFFFAOYSA-N 3-[7-(1-benzofuran-2-ylmethylamino)-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1C(C(=CC=C2)NCC=3OC4=CC=CC=C4C=3)=C2C(=O)N1C1CCC(=O)NC1=O UZHODHVYNPJSAE-UHFFFAOYSA-N 0.000 claims 1
- YTZHBIQRPRJGIS-UHFFFAOYSA-N 3-[7-[(4,5-dimethylfuran-2-yl)methylamino]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O1C(C)=C(C)C=C1CNC1=CC=CC2=C1CN(C1C(NC(=O)CC1)=O)C2=O YTZHBIQRPRJGIS-UHFFFAOYSA-N 0.000 claims 1
- DUKMMRZCLZQKNO-UHFFFAOYSA-N 3-[7-[(5-methylfuran-2-yl)methylamino]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O1C(C)=CC=C1CNC1=CC=CC2=C1CN(C1C(NC(=O)CC1)=O)C2=O DUKMMRZCLZQKNO-UHFFFAOYSA-N 0.000 claims 1
- LMUICIDWYMVFIY-UHFFFAOYSA-N 3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-1,1-dimethylurea Chemical compound O=C1C=2C(CNC(=O)N(C)C)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O LMUICIDWYMVFIY-UHFFFAOYSA-N 0.000 claims 1
- LZCFWOMFHZEFHH-UHFFFAOYSA-N 3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-1,1-dimethylurea Chemical compound C1C=2C(CNC(=O)N(C)C)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O LZCFWOMFHZEFHH-UHFFFAOYSA-N 0.000 claims 1
- MYIIICZTZCDJOP-UHFFFAOYSA-N 3-amino-n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]propanamide;hydrochloride Chemical compound Cl.C1C=2C(CNC(=O)CCN)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O MYIIICZTZCDJOP-UHFFFAOYSA-N 0.000 claims 1
- FESDGMBMAGDYQM-UHFFFAOYSA-N 3-chloro-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-4-methylbenzamide Chemical compound C1=C(Cl)C(C)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O FESDGMBMAGDYQM-UHFFFAOYSA-N 0.000 claims 1
- YFCOKKDIZSBXCG-UHFFFAOYSA-N 3-chloro-n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]benzamide Chemical compound ClC1=CC=CC(C(=O)NCC=2C=3CN(C(=O)C=3C=CC=2)C2C(NC(=O)CC2)=O)=C1 YFCOKKDIZSBXCG-UHFFFAOYSA-N 0.000 claims 1
- VCNABSDAEWPOOO-UHFFFAOYSA-N 3-cyano-n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]benzamide Chemical compound C=1C=CC(C#N)=CC=1C(=O)NCC(C=1C2)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O VCNABSDAEWPOOO-UHFFFAOYSA-N 0.000 claims 1
- LVCLQSUXKROPMY-UHFFFAOYSA-N 4-(1,3-benzodioxol-5-ylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1C(C(=CC=C2)NC=3C=C4OCOC4=CC=3)=C2C(=O)N1C1CCC(=O)NC1=O LVCLQSUXKROPMY-UHFFFAOYSA-N 0.000 claims 1
- RYURXHSXGWODSF-UHFFFAOYSA-N 4-(2,3-dihydro-1h-inden-5-ylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1C(C(=CC=C2)NC=3C=C4CCCC4=CC=3)=C2C(=O)N1C1CCC(=O)NC1=O RYURXHSXGWODSF-UHFFFAOYSA-N 0.000 claims 1
- DUAADHYMSZQANS-QHCPKHFHSA-N 4-(2,3-dihydro-1h-inden-5-ylamino)-2-[(3s)-3-methyl-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC(NC=3C=C4CCCC4=CC=3)=C2C(=O)N1[C@@]1(C)CCC(=O)NC1=O DUAADHYMSZQANS-QHCPKHFHSA-N 0.000 claims 1
- MRIHLIRCTOOZIX-UHFFFAOYSA-N 4-(2,4-dimethoxyanilino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound COC1=CC(OC)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O MRIHLIRCTOOZIX-UHFFFAOYSA-N 0.000 claims 1
- XNPDMZOMFKOCLF-QFIPXVFZSA-N 4-(2,4-dimethoxyanilino)-2-[(3s)-3-methyl-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound COC1=CC(OC)=CC=C1NC1=CC=CC2=C1C(=O)N([C@]1(C)C(NC(=O)CC1)=O)C2=O XNPDMZOMFKOCLF-QFIPXVFZSA-N 0.000 claims 1
- FQOBRIMZERWFKV-UHFFFAOYSA-N 4-(2,5-dimethoxyanilino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound COC1=CC=C(OC)C(NC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 FQOBRIMZERWFKV-UHFFFAOYSA-N 0.000 claims 1
- YXQWATKUGRXZJR-UHFFFAOYSA-N 4-(3,4-dimethoxyanilino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C1=C(OC)C(OC)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O YXQWATKUGRXZJR-UHFFFAOYSA-N 0.000 claims 1
- KFNUNWUCPRDONR-UHFFFAOYSA-N 4-(4-cyclohexylanilino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1C(C(=CC=C2)NC=3C=CC(=CC=3)C3CCCCC3)=C2C(=O)N1C1CCC(=O)NC1=O KFNUNWUCPRDONR-UHFFFAOYSA-N 0.000 claims 1
- RZQMCTNESRFSRS-UHFFFAOYSA-N 4-(4-tert-butylanilino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C1=CC(C(C)(C)C)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O RZQMCTNESRFSRS-UHFFFAOYSA-N 0.000 claims 1
- BHAWWZJZGQTPRR-UHFFFAOYSA-N 4-(cyclopropylmethylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1C(C(=CC=C2)NCC3CC3)=C2C(=O)N1C1CCC(=O)NC1=O BHAWWZJZGQTPRR-UHFFFAOYSA-N 0.000 claims 1
- AWXVBAQGKDDDPD-UHFFFAOYSA-N 4-(difluoromethoxy)-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]benzamide Chemical compound C1=CC(OC(F)F)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O AWXVBAQGKDDDPD-UHFFFAOYSA-N 0.000 claims 1
- INKYIHAAXKWSIM-UHFFFAOYSA-N 4-(furan-2-ylmethylamino)-2-(3-methyl-2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC(NCC=3OC=CC=3)=C2C(=O)N1C1(C)CCC(=O)NC1=O INKYIHAAXKWSIM-UHFFFAOYSA-N 0.000 claims 1
- BGSYKVLJNVCKOC-UHFFFAOYSA-N 4-[2-[2-(dimethylamino)ethoxy]-4-methoxyanilino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione;hydrochloride Chemical compound Cl.CN(C)CCOC1=CC(OC)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O BGSYKVLJNVCKOC-UHFFFAOYSA-N 0.000 claims 1
- ZYNOSWNDBAKLKV-UHFFFAOYSA-N 4-[4-(dimethylamino)anilino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C1=CC(N(C)C)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O ZYNOSWNDBAKLKV-UHFFFAOYSA-N 0.000 claims 1
- BQXOTKCLUGMWSD-UHFFFAOYSA-N 4-[4-[(dimethylamino)methyl]-2-methoxyanilino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound COC1=CC(CN(C)C)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O BQXOTKCLUGMWSD-UHFFFAOYSA-N 0.000 claims 1
- HWTRJXYGHZAWPX-UHFFFAOYSA-N 4-[4-[(dimethylamino)methyl]-2-methoxyanilino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione;hydrochloride Chemical compound Cl.COC1=CC(CN(C)C)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O HWTRJXYGHZAWPX-UHFFFAOYSA-N 0.000 claims 1
- WJDXYSZBKRWFJL-UHFFFAOYSA-N 4-[4-[2-(dimethylamino)ethoxy]-2-methoxyanilino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione;hydrochloride Chemical compound Cl.COC1=CC(OCCN(C)C)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O WJDXYSZBKRWFJL-UHFFFAOYSA-N 0.000 claims 1
- QOKMWTRIVMEYBS-UHFFFAOYSA-N 4-[4-[2-(dimethylamino)ethoxy]-2-phenoxyanilino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C=1C=CC=CC=1OC1=CC(OCCN(C)C)=CC=C1NC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O QOKMWTRIVMEYBS-UHFFFAOYSA-N 0.000 claims 1
- ANQFRODHTXHYAR-UHFFFAOYSA-N 4-[4-[2-(dimethylamino)ethoxy]-2-propan-2-yloxyanilino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound CC(C)OC1=CC(OCCN(C)C)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O ANQFRODHTXHYAR-UHFFFAOYSA-N 0.000 claims 1
- JCCXNEPHUMBTEV-UHFFFAOYSA-N 4-[4-[2-(dimethylamino)ethoxy]anilino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C1=CC(OCCN(C)C)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O JCCXNEPHUMBTEV-UHFFFAOYSA-N 0.000 claims 1
- ZCZBRGXXIWJPFM-UHFFFAOYSA-N 4-[4-[3-(dimethylamino)propoxy]-2-methoxyanilino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione;hydrochloride Chemical compound Cl.COC1=CC(OCCCN(C)C)=CC=C1NC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O ZCZBRGXXIWJPFM-UHFFFAOYSA-N 0.000 claims 1
- OFKRVYXIVMPERE-UHFFFAOYSA-N 4-[[2-(azetidin-1-yl)-2-oxoethyl]amino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C1CCN1C(=O)CNC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O OFKRVYXIVMPERE-UHFFFAOYSA-N 0.000 claims 1
- MEYKZCUSYIEQSY-UHFFFAOYSA-N 4-anilino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1C(C(=CC=C2)NC=3C=CC=CC=3)=C2C(=O)N1C1CCC(=O)NC1=O MEYKZCUSYIEQSY-UHFFFAOYSA-N 0.000 claims 1
- HPTMJOQXHFJPJA-UHFFFAOYSA-N 4-chloro-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O HPTMJOQXHFJPJA-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- YJLVXTLDSBUIOA-UHFFFAOYSA-N N-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-(1H-pyridin-2-ylidene)acetamide Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)CNC(C=C1NC=CC=C1)=O)=O)=O YJLVXTLDSBUIOA-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- FDTXGKMIVHIXPL-UHFFFAOYSA-N [2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methylurea Chemical compound O=C1C=2C(CNC(=O)N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O FDTXGKMIVHIXPL-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000034737 hemoglobinopathy Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- CWOIZCCZTOSPDP-UHFFFAOYSA-N methyl 2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]acetate Chemical compound O=C1C=2C(NCC(=O)OC)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O CWOIZCCZTOSPDP-UHFFFAOYSA-N 0.000 claims 1
- SKNKQGAZDDTXLJ-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-(1-methylindol-3-yl)acetamide Chemical compound C12=CC=CC=C2N(C)C=C1CC(=O)NCC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O SKNKQGAZDDTXLJ-UHFFFAOYSA-N 0.000 claims 1
- MBPJSTFGXSFNSD-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-(2-fluorophenyl)acetamide Chemical compound FC1=CC=CC=C1CC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O MBPJSTFGXSFNSD-UHFFFAOYSA-N 0.000 claims 1
- IGSLDIFIQZWOFM-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-(3-fluoro-4-methylphenyl)acetamide Chemical compound C1=C(F)C(C)=CC=C1CC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O IGSLDIFIQZWOFM-UHFFFAOYSA-N 0.000 claims 1
- ABMSNQBPFZHMHQ-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-(3-fluorophenyl)acetamide Chemical compound FC1=CC=CC(CC(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 ABMSNQBPFZHMHQ-UHFFFAOYSA-N 0.000 claims 1
- QVOPBUFFQDLSNC-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-(3-methyl-1,2-oxazol-5-yl)acetamide Chemical compound O1N=C(C)C=C1CC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O QVOPBUFFQDLSNC-UHFFFAOYSA-N 0.000 claims 1
- NIGCVMMXGXBMCN-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O NIGCVMMXGXBMCN-UHFFFAOYSA-N 0.000 claims 1
- OGYVLMSRCLXRME-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-(6-methoxy-1-benzofuran-3-yl)acetamide Chemical compound C=1OC2=CC(OC)=CC=C2C=1CC(=O)NCC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O OGYVLMSRCLXRME-UHFFFAOYSA-N 0.000 claims 1
- CZLPDAAIOCKUTO-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-[3-(trifluoromethoxy)phenyl]acetamide Chemical compound FC(F)(F)OC1=CC=CC(CC(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 CZLPDAAIOCKUTO-UHFFFAOYSA-N 0.000 claims 1
- YRYWLHXVHFMSJT-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC=CC(CC(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 YRYWLHXVHFMSJT-UHFFFAOYSA-N 0.000 claims 1
- GGYVNBOYPCLJOJ-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-[4-(trifluoromethoxy)phenyl]acetamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O GGYVNBOYPCLJOJ-UHFFFAOYSA-N 0.000 claims 1
- WOAXEMHAYVKRQL-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]acetamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CC(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O WOAXEMHAYVKRQL-UHFFFAOYSA-N 0.000 claims 1
- YKDFAWCTKUWAFG-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-fluoro-3-(trifluoromethyl)benzamide Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O YKDFAWCTKUWAFG-UHFFFAOYSA-N 0.000 claims 1
- ITBPHOIJFFNTRH-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-fluoro-4-(trifluoromethyl)benzamide Chemical compound FC1=CC(C(F)(F)F)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O ITBPHOIJFFNTRH-UHFFFAOYSA-N 0.000 claims 1
- BYKYVELOHNBYRI-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-naphthalen-1-ylacetamide Chemical compound C=1C=CC2=CC=CC=C2C=1CC(=O)NCC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O BYKYVELOHNBYRI-UHFFFAOYSA-N 0.000 claims 1
- XROTVQRDACDPAF-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-2-pyridin-4-ylacetamide Chemical compound C=1C=CC=2C(=O)N(C3C(NC(=O)CC3)=O)C(=O)C=2C=1CNC(=O)CC1=CC=NC=C1 XROTVQRDACDPAF-UHFFFAOYSA-N 0.000 claims 1
- HOFYMLZLENFFTH-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O HOFYMLZLENFFTH-UHFFFAOYSA-N 0.000 claims 1
- LVTDVNVMHJLRGG-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3,5-difluorobenzamide Chemical compound FC1=CC(F)=CC(C(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 LVTDVNVMHJLRGG-UHFFFAOYSA-N 0.000 claims 1
- VSWIOXGJWZALGG-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-(trifluoromethoxy)benzamide Chemical compound FC(F)(F)OC1=CC=CC(C(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 VSWIOXGJWZALGG-UHFFFAOYSA-N 0.000 claims 1
- DYXHZYRTBDHBOH-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 DYXHZYRTBDHBOH-UHFFFAOYSA-N 0.000 claims 1
- GLPHGRIJPCJBAI-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-fluoro-4-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(F)=CC(C(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 GLPHGRIJPCJBAI-UHFFFAOYSA-N 0.000 claims 1
- KZOIICOOAIQLTR-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-fluorobenzamide Chemical compound FC1=CC=CC(C(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 KZOIICOOAIQLTR-UHFFFAOYSA-N 0.000 claims 1
- VQOBKPYYWKEYQS-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NCC=2C=3C(=O)N(C4C(NC(=O)CC4)=O)C(=O)C=3C=CC=2)=C1 VQOBKPYYWKEYQS-UHFFFAOYSA-N 0.000 claims 1
- DYZYUVCJNLJJRA-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-4-(trifluoromethoxy)benzamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O DYZYUVCJNLJJRA-UHFFFAOYSA-N 0.000 claims 1
- MSBAMPJGHODANU-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-4-(trifluoromethyl)benzamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O MSBAMPJGHODANU-UHFFFAOYSA-N 0.000 claims 1
- UQKPMOJZBCVTCM-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-4-fluoro-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O UQKPMOJZBCVTCM-UHFFFAOYSA-N 0.000 claims 1
- LDWNRNCXMODFJG-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-4-fluorobenzamide Chemical compound C1=CC(F)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O LDWNRNCXMODFJG-UHFFFAOYSA-N 0.000 claims 1
- BMWMIHYPEGYKPV-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O BMWMIHYPEGYKPV-UHFFFAOYSA-N 0.000 claims 1
- DBODWBZVRFTANI-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)NCC1=CC=CC2=C1C(=O)N(C1C(NC(=O)CC1)=O)C2=O DBODWBZVRFTANI-UHFFFAOYSA-N 0.000 claims 1
- FFSGJTPGGZCUPV-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-2-methoxyacetamide Chemical compound C1C=2C(CNC(=O)COC)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O FFSGJTPGGZCUPV-UHFFFAOYSA-N 0.000 claims 1
- WFSLTXJWUZXYOW-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(=O)NCC1=CC=CC2=C1CN(C1C(NC(=O)CC1)=O)C2=O WFSLTXJWUZXYOW-UHFFFAOYSA-N 0.000 claims 1
- WQBKCQLZRIAQIC-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-2-phenylacetamide Chemical compound C=1C=CC=2C(=O)N(C3C(NC(=O)CC3)=O)CC=2C=1CNC(=O)CC1=CC=CC=C1 WQBKCQLZRIAQIC-UHFFFAOYSA-N 0.000 claims 1
- HPTJNUKLJJOMFF-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NCC=2C=3CN(C(=O)C=3C=CC=2)C2C(NC(=O)CC2)=O)=C1 HPTJNUKLJJOMFF-UHFFFAOYSA-N 0.000 claims 1
- XKJJYMQLQUFZHC-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NCC=2C=3CN(C(=O)C=3C=CC=2)C2C(NC(=O)CC2)=O)=C1 XKJJYMQLQUFZHC-UHFFFAOYSA-N 0.000 claims 1
- YFZQFLPZSCFTFN-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NCC1=CC=CC2=C1CN(C1C(NC(=O)CC1)=O)C2=O YFZQFLPZSCFTFN-UHFFFAOYSA-N 0.000 claims 1
- SPQGRSKDQIJOBF-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NCC(C=1C2)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O SPQGRSKDQIJOBF-UHFFFAOYSA-N 0.000 claims 1
- VKUCWMMQPDTDRL-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]butanamide Chemical compound C1C=2C(CNC(=O)CCC)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O VKUCWMMQPDTDRL-UHFFFAOYSA-N 0.000 claims 1
- QGZJQKIQWRSCBD-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NCC(C=1C2)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O QGZJQKIQWRSCBD-UHFFFAOYSA-N 0.000 claims 1
- AJUIBCLFLJJGIC-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]pyridine-4-carboxamide Chemical compound C=1C=NC=CC=1C(=O)NCC(C=1C2)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O AJUIBCLFLJJGIC-UHFFFAOYSA-N 0.000 claims 1
- UAYIFYKZKRYQEO-UHFFFAOYSA-N n-cyclopropyl-2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]acetamide Chemical compound C1CC1NC(=O)CNC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O UAYIFYKZKRYQEO-UHFFFAOYSA-N 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 claims 1
- LHTOJIYIZRLPLM-UHFFFAOYSA-N tert-butyl n-[4-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methylamino]-4-oxobutyl]carbamate Chemical compound C1C=2C(CNC(=O)CCCNC(=O)OC(C)(C)C)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O LHTOJIYIZRLPLM-UHFFFAOYSA-N 0.000 claims 1
- QPYDRCOBUFLJAS-UHFFFAOYSA-N tert-butyl n-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]methyl]carbamate Chemical compound C1C=2C(CNC(=O)OC(C)(C)C)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O QPYDRCOBUFLJAS-UHFFFAOYSA-N 0.000 claims 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 abstract 1
- 0 CCCc(cccc1)c1C(NCc1cccc2c1CC(CC(CCC(N1)=O)C1=O)C2=*)=O Chemical compound CCCc(cccc1)c1C(NCc1cccc2c1CC(CC(CCC(N1)=O)C1=O)C2=*)=O 0.000 description 10
- DUAADHYMSZQANS-UHFFFAOYSA-N CC(CCC(N1)=O)(C1=O)N(C(c1c2c(Nc3ccc(CCC4)c4c3)ccc1)=O)C2=O Chemical compound CC(CCC(N1)=O)(C1=O)N(C(c1c2c(Nc3ccc(CCC4)c4c3)ccc1)=O)C2=O DUAADHYMSZQANS-UHFFFAOYSA-N 0.000 description 1
- HBSLGRSVWFMOCA-OQLLNIDSSA-N CCCC(NCc1cccc(C2=O)c1C/C2=C\C(CCC(C1)=O)C1=O)=O Chemical compound CCCC(NCc1cccc(C2=O)c1C/C2=C\C(CCC(C1)=O)C1=O)=O HBSLGRSVWFMOCA-OQLLNIDSSA-N 0.000 description 1
- AVWOLGITZBQHDU-UHFFFAOYSA-N CCCCc1ccc(C(NCc2cccc(C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)=O)nc1 Chemical compound CCCCc1ccc(C(NCc2cccc(C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)=O)nc1 AVWOLGITZBQHDU-UHFFFAOYSA-N 0.000 description 1
- VKIZCHXSFAURCT-UHFFFAOYSA-N O=C(c1cc(Cl)cnc1Cl)NCc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound O=C(c1cc(Cl)cnc1Cl)NCc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O VKIZCHXSFAURCT-UHFFFAOYSA-N 0.000 description 1
- KKTHENGGXPWIDT-UHFFFAOYSA-N O=C(c1cc(OC(F)(F)F)ccc1)NCC(C=CCC1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O Chemical compound O=C(c1cc(OC(F)(F)F)ccc1)NCC(C=CCC1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O KKTHENGGXPWIDT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71238705P | 2005-08-31 | 2005-08-31 | |
| US60/712,387 | 2005-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008112221A true RU2008112221A (ru) | 2009-10-10 |
Family
ID=37758733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008112221/04A RU2008112221A (ru) | 2005-08-31 | 2006-08-25 | Соединения ряда изоиндолимидов, их композиции и способы применения |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20070049618A1 (https=) |
| EP (1) | EP1919892B1 (https=) |
| JP (1) | JP5578785B2 (https=) |
| KR (1) | KR20080042158A (https=) |
| CN (1) | CN101291924A (https=) |
| AR (1) | AR055150A1 (https=) |
| AU (1) | AU2006285144A1 (https=) |
| BR (1) | BRPI0614995A2 (https=) |
| CA (3) | CA2822094C (https=) |
| CR (1) | CR9772A (https=) |
| DO (1) | DOP2006000193A (https=) |
| EC (1) | ECSP088332A (https=) |
| ES (1) | ES2434946T3 (https=) |
| GT (1) | GT200600398A (https=) |
| IL (1) | IL189795A0 (https=) |
| MX (1) | MX2008002765A (https=) |
| NO (1) | NO20081554L (https=) |
| PA (1) | PA8693101A1 (https=) |
| PE (1) | PE20070541A1 (https=) |
| RU (1) | RU2008112221A (https=) |
| TW (1) | TW200745078A (https=) |
| UA (1) | UA91560C2 (https=) |
| WO (1) | WO2007027527A2 (https=) |
| ZA (1) | ZA200802490B (https=) |
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2567753C2 (ru) * | 2010-02-11 | 2015-11-10 | Селджин Корпорейшн | Производные арилметокси изоиндолина и композиции, включающие их, и способы их применения |
| RU2695521C2 (ru) * | 2014-10-30 | 2019-07-23 | Канпу Биофармасьютикалс, Лтд. | Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение |
| US10584101B2 (en) | 2016-10-11 | 2020-03-10 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US10604506B2 (en) | 2017-01-26 | 2020-03-31 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| US10647698B2 (en) | 2016-12-01 | 2020-05-12 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| US10723717B2 (en) | 2016-12-23 | 2020-07-28 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| RU2738833C2 (ru) * | 2014-04-14 | 2020-12-17 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| US10946017B2 (en) | 2015-06-05 | 2021-03-16 | Arvinas Operations, Inc. | Tank-binding kinase-1 PROTACs and associated methods of use |
| US10994015B2 (en) | 2016-12-23 | 2021-05-04 | Arvinas Operations, Inc. | EGFR proteolysis targeting chimeric molecules and associated methods of use |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| US11161841B2 (en) | 2018-04-04 | 2021-11-02 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| US11352351B2 (en) | 2015-01-20 | 2022-06-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US11427548B2 (en) | 2015-01-20 | 2022-08-30 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US11458123B2 (en) | 2016-11-01 | 2022-10-04 | Arvinas Operations, Inc. | Tau-protein targeting PROTACs and associated methods of use |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| US11883393B2 (en) | 2019-12-19 | 2024-01-30 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
| US11986532B2 (en) | 2021-04-16 | 2024-05-21 | Arvinas Operations, Inc. | Modulators of BCL6 proteolysis and associated methods of use |
| US12043612B2 (en) | 2020-05-09 | 2024-07-23 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same |
| US12162859B2 (en) | 2020-09-14 | 2024-12-10 | Arvinas Operations, Inc. | Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| US12208095B2 (en) | 2019-08-26 | 2025-01-28 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| US12239711B2 (en) | 2014-04-14 | 2025-03-04 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US12310975B2 (en) | 2019-10-17 | 2025-05-27 | Arvinas Operations, Inc. | Modulators of BCL6 proteolysis and associated methods of use |
| US12441708B2 (en) | 2017-01-31 | 2025-10-14 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| US12496301B2 (en) | 2023-12-08 | 2025-12-16 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| US12569464B2 (en) | 2016-04-05 | 2026-03-10 | Arvinas Operations, Inc. | Protein-protein interaction inducing technology |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1797068B1 (en) * | 2004-09-03 | 2013-10-09 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
| MX2007016290A (es) | 2005-06-30 | 2008-03-10 | Celgene Corp | Procesos para la preparacion de compuestos de 4-amino-2(2,6-dioxopiperidin-3-il)isoindolin-1,3-diona. |
| UA91560C2 (ru) * | 2005-08-31 | 2010-08-10 | Селджин Корпорэйшн | Соединения ряда изоиндолимидов, их композиция и применение |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| CA2704710C (en) | 2007-09-26 | 2016-02-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same |
| EP2235535B1 (en) * | 2007-12-07 | 2014-11-12 | Celgene Corporation | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma |
| WO2009085234A2 (en) | 2007-12-20 | 2009-07-09 | Signal Pharmaceuticals, Inc. | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| WO2009105256A2 (en) * | 2008-02-20 | 2009-08-27 | Celgene Corporation | Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand |
| PT2358697E (pt) * | 2008-10-29 | 2016-02-03 | Celgene Corp | Compostos de isoindolina para utilização no tratamento do cancro |
| EP3489352A1 (en) | 2009-03-25 | 2019-05-29 | Celularity, Inc. | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
| EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
| MX337566B (es) | 2010-01-05 | 2016-03-10 | Celgene Corp | Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer. |
| EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| WO2012145309A1 (en) | 2011-04-18 | 2012-10-26 | Celgene Corporation | Biomarkers for the treatment of multiple myeloma |
| AU2012249491B2 (en) | 2011-04-29 | 2016-12-15 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| JP6359563B2 (ja) | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 |
| CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| NZ629456A (en) | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| CN103396397A (zh) * | 2013-08-14 | 2013-11-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 来那度胺衍生物及其作为药物的用途 |
| PL3040329T3 (pl) * | 2013-08-29 | 2019-04-30 | Kyoto Pharma Ind | Związek aromatyczny i jego zastosowanie w leczeniu chorób związanych z metabolizmem kości |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| EP3827836A1 (en) | 2014-06-27 | 2021-06-02 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| EP3317287B1 (en) | 2015-07-02 | 2019-07-31 | GlaxoSmithKline Intellectual Property Development Limited | Inhibitors of indoleamine 2,3-dioxygenase |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| US10759808B2 (en) * | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| AU2019212093B2 (en) | 2018-01-26 | 2024-05-30 | Recordati Industria Chimica E Farmaceutica S.P.A | Triazole, imidazole and pyrrole condensed piperazine derivatives and their use as modulators of mGlu5 receptors |
| WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
| BR112020017053A2 (pt) | 2018-02-21 | 2020-12-15 | Celgene Corporation | Anticorpos que se ligam ao bcma e usos dos mesmos |
| FI3784663T3 (fi) | 2018-04-23 | 2023-10-06 | Celgene Corp | Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi |
| AU2019294835B2 (en) * | 2018-06-29 | 2025-04-17 | Dana-Farber Cancer Institute, Inc. | Ligands to cereblon (CRBN) |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| AU2019348094B2 (en) * | 2018-09-30 | 2022-12-22 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, preparation method, pharmaceutical composition and use thereof |
| WO2020102195A1 (en) | 2018-11-13 | 2020-05-22 | Biotheryx, Inc. | Substituted isoindolinones |
| WO2020114482A1 (zh) | 2018-12-06 | 2020-06-11 | 中国科学院上海药物研究所 | 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用 |
| CN111747924B (zh) * | 2019-03-29 | 2023-11-10 | 华东师范大学 | 一类来那度胺/泊马度胺类似物及其应用 |
| KR102913106B1 (ko) | 2019-05-31 | 2026-01-19 | 셀진 코포레이션 | 치환된 1-옥소-이소인돌린-5-카르복스아미드 화합물, 그의 조성물 및 그를 사용한 치료 방법 |
| EP4110772A4 (en) | 2020-02-26 | 2024-04-03 | Cullgen (Shanghai), Inc. | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE |
| CN114057592B (zh) * | 2020-08-05 | 2023-08-22 | 沈阳化工研究院有限公司 | 一种制备4-氨基甲基苯甲酸的方法 |
| US20230310478A1 (en) * | 2020-09-02 | 2023-10-05 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and compositions for the treatment of pulmonary hypertension and cancer |
| EP4217352A4 (en) | 2020-09-23 | 2024-04-10 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
| CN114591192B (zh) * | 2020-12-04 | 2024-06-21 | 江西仰立新材料有限公司 | 一种n-环丙甲基苯胺类化合物的制备方法 |
| CN116368131B (zh) * | 2021-01-11 | 2024-09-20 | 和径医药科技（上海）有限公司 | 一类新型Smad3蛋白降解剂及其应用 |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| US12599625B2 (en) | 2021-05-13 | 2026-04-14 | Penland Foundation | Treatment of ARDS and other conditions caused by acutely elevated cytokine levels and post ARDS chronic cytokine production using inhaled anesthetics |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| WO2023287726A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of cancer using botulinum toxin and nitrous oxide |
| WO2023081224A1 (en) * | 2021-11-03 | 2023-05-11 | St. Jude Children's Research Hospital, Inc. | Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4- yl)methyl)benzamide analogs as modulators of cereblon protein |
| EP4612128A4 (en) * | 2022-11-04 | 2025-09-10 | Bristol Myers Squibb Co | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
| CN116473975B (zh) * | 2023-04-11 | 2026-03-13 | 东南大学 | 奥沙普秦和异烟酰胺或吡嗪酰胺低共熔物、药物组合物及其制备方法 |
| WO2024222918A1 (zh) * | 2023-04-28 | 2024-10-31 | 中国药科大学 | 一种苯并六元杂环类gspt1蛋白降解剂及其应用 |
| KR20250054737A (ko) * | 2023-10-16 | 2025-04-23 | 주식회사 아스트로젠 | 신규한 분자 접착제의 용도 |
| CN120289981B (zh) * | 2025-06-13 | 2025-08-29 | 兴邦新材料(山东)有限公司 | 高尺寸稳定性的tpu材料及其制备方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB508048A (en) | 1937-12-24 | 1939-06-26 | Marconi Wireless Telegraph Co | Improvements in or relating to aerial systems |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| DE122007000079I2 (de) | 1996-07-24 | 2010-08-12 | Celgene Corp | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| KR19980074060A (ko) * | 1997-03-21 | 1998-11-05 | 김윤배 | 신규한 치환된 3,4-디알콕시페닐 유도체 |
| TR200101502T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| JP2001106673A (ja) * | 1999-07-26 | 2001-04-17 | Banyu Pharmaceut Co Ltd | ビアリールウレア誘導体 |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| GB0124627D0 (en) * | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| UA91560C2 (ru) * | 2005-08-31 | 2010-08-10 | Селджин Корпорэйшн | Соединения ряда изоиндолимидов, их композиция и применение |
| US8590505B2 (en) | 2008-07-03 | 2013-11-26 | Dow Global Technologies Llc | Method of operating a compression ignition internal combustion engine |
| KR20160100584A (ko) | 2015-02-16 | 2016-08-24 | 에스케이하이닉스 주식회사 | 반도체 메모리 장치 및 그의 테스트 방법 |
-
2006
- 2006-08-25 UA UAA200803946A patent/UA91560C2/ru unknown
- 2006-08-25 WO PCT/US2006/033278 patent/WO2007027527A2/en not_active Ceased
- 2006-08-25 BR BRPI0614995-2A patent/BRPI0614995A2/pt not_active IP Right Cessation
- 2006-08-25 ES ES06813767T patent/ES2434946T3/es active Active
- 2006-08-25 JP JP2008529132A patent/JP5578785B2/ja active Active
- 2006-08-25 RU RU2008112221/04A patent/RU2008112221A/ru not_active Application Discontinuation
- 2006-08-25 CA CA2822094A patent/CA2822094C/en active Active
- 2006-08-25 KR KR1020087007833A patent/KR20080042158A/ko not_active Withdrawn
- 2006-08-25 EP EP06813767.8A patent/EP1919892B1/en active Active
- 2006-08-25 CA CA2899923A patent/CA2899923A1/en not_active Abandoned
- 2006-08-25 AU AU2006285144A patent/AU2006285144A1/en not_active Abandoned
- 2006-08-25 CA CA2620085A patent/CA2620085C/en active Active
- 2006-08-25 MX MX2008002765A patent/MX2008002765A/es not_active Application Discontinuation
- 2006-08-25 CN CNA2006800393786A patent/CN101291924A/zh active Pending
- 2006-08-25 ZA ZA200802490A patent/ZA200802490B/xx unknown
- 2006-08-30 TW TW095132015A patent/TW200745078A/zh unknown
- 2006-08-30 US US11/513,563 patent/US20070049618A1/en not_active Abandoned
- 2006-08-30 PA PA20068693101A patent/PA8693101A1/es unknown
- 2006-08-31 DO DO2006000193A patent/DOP2006000193A/es unknown
- 2006-08-31 AR ARP060103821A patent/AR055150A1/es unknown
- 2006-08-31 PE PE2006001061A patent/PE20070541A1/es not_active Application Discontinuation
- 2006-08-31 GT GT200600398A patent/GT200600398A/es unknown
-
2008
- 2008-02-26 IL IL189795A patent/IL189795A0/en unknown
- 2008-02-28 CR CR9772A patent/CR9772A/es not_active Application Discontinuation
- 2008-03-28 NO NO20081554A patent/NO20081554L/no not_active Application Discontinuation
- 2008-03-31 EC EC2008008332A patent/ECSP088332A/es unknown
-
2011
- 2011-02-17 US US13/030,075 patent/US8481568B2/en active Active
Cited By (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2567753C2 (ru) * | 2010-02-11 | 2015-11-10 | Селджин Корпорейшн | Производные арилметокси изоиндолина и композиции, включающие их, и способы их применения |
| RU2738833C2 (ru) * | 2014-04-14 | 2020-12-17 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| RU2738833C9 (ru) * | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| US12239711B2 (en) | 2014-04-14 | 2025-03-04 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| RU2695521C2 (ru) * | 2014-10-30 | 2019-07-23 | Канпу Биофармасьютикалс, Лтд. | Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение |
| RU2695521C9 (ru) * | 2014-10-30 | 2019-08-19 | Канпу Биофармасьютикалс, Лтд. | Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение |
| US11427548B2 (en) | 2015-01-20 | 2022-08-30 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US11352351B2 (en) | 2015-01-20 | 2022-06-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US10946017B2 (en) | 2015-06-05 | 2021-03-16 | Arvinas Operations, Inc. | Tank-binding kinase-1 PROTACs and associated methods of use |
| US12171831B2 (en) | 2015-08-19 | 2024-12-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain- containing proteins |
| US11554171B2 (en) | 2015-08-19 | 2023-01-17 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US12569464B2 (en) | 2016-04-05 | 2026-03-10 | Arvinas Operations, Inc. | Protein-protein interaction inducing technology |
| US11964945B2 (en) | 2016-10-11 | 2024-04-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US12077509B2 (en) | 2016-10-11 | 2024-09-03 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US10844021B2 (en) | 2016-10-11 | 2020-11-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US11236051B2 (en) | 2016-10-11 | 2022-02-01 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US11952347B2 (en) | 2016-10-11 | 2024-04-09 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US10584101B2 (en) | 2016-10-11 | 2020-03-10 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US11458123B2 (en) | 2016-11-01 | 2022-10-04 | Arvinas Operations, Inc. | Tau-protein targeting PROTACs and associated methods of use |
| US11104666B2 (en) | 2016-12-01 | 2021-08-31 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| US12172981B2 (en) | 2016-12-01 | 2024-12-24 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| US10647698B2 (en) | 2016-12-01 | 2020-05-12 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| US11597720B2 (en) | 2016-12-01 | 2023-03-07 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| US10899742B1 (en) | 2016-12-01 | 2021-01-26 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| US10994015B2 (en) | 2016-12-23 | 2021-05-04 | Arvinas Operations, Inc. | EGFR proteolysis targeting chimeric molecules and associated methods of use |
| US10723717B2 (en) | 2016-12-23 | 2020-07-28 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US11986531B2 (en) | 2016-12-23 | 2024-05-21 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| US11857519B2 (en) | 2016-12-24 | 2024-01-02 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| US11384063B2 (en) | 2017-01-26 | 2022-07-12 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| US12275716B2 (en) | 2017-01-26 | 2025-04-15 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| US10604506B2 (en) | 2017-01-26 | 2020-03-31 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| US12441708B2 (en) | 2017-01-31 | 2025-10-14 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US12036209B2 (en) | 2017-11-17 | 2024-07-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| US12552783B2 (en) | 2018-04-04 | 2026-02-17 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| US11161841B2 (en) | 2018-04-04 | 2021-11-02 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| US12594264B2 (en) | 2018-08-20 | 2026-04-07 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| US12559486B2 (en) | 2019-07-17 | 2026-02-24 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
| US12208095B2 (en) | 2019-08-26 | 2025-01-28 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| US12310975B2 (en) | 2019-10-17 | 2025-05-27 | Arvinas Operations, Inc. | Modulators of BCL6 proteolysis and associated methods of use |
| US11883393B2 (en) | 2019-12-19 | 2024-01-30 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US12427144B2 (en) | 2019-12-19 | 2025-09-30 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US12043612B2 (en) | 2020-05-09 | 2024-07-23 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| US12162859B2 (en) | 2020-09-14 | 2024-12-10 | Arvinas Operations, Inc. | Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor |
| US11986532B2 (en) | 2021-04-16 | 2024-05-21 | Arvinas Operations, Inc. | Modulators of BCL6 proteolysis and associated methods of use |
| US12156916B2 (en) | 2022-09-07 | 2024-12-03 | Arvinas Operations, Inc. | Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| US12496301B2 (en) | 2023-12-08 | 2025-12-16 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2620085A1 (en) | 2007-03-08 |
| EP1919892B1 (en) | 2013-08-14 |
| CN101291924A (zh) | 2008-10-22 |
| MX2008002765A (es) | 2008-04-07 |
| US20110144158A1 (en) | 2011-06-16 |
| WO2007027527A2 (en) | 2007-03-08 |
| PE20070541A1 (es) | 2007-08-10 |
| UA91560C2 (ru) | 2010-08-10 |
| CA2822094C (en) | 2015-10-27 |
| GT200600398A (es) | 2007-05-15 |
| AU2006285144A1 (en) | 2007-03-08 |
| US8481568B2 (en) | 2013-07-09 |
| BRPI0614995A2 (pt) | 2010-01-12 |
| JP5578785B2 (ja) | 2014-08-27 |
| CR9772A (es) | 2008-07-24 |
| ECSP088332A (es) | 2008-04-28 |
| IL189795A0 (en) | 2008-08-07 |
| KR20080042158A (ko) | 2008-05-14 |
| ES2434946T3 (es) | 2013-12-18 |
| CA2822094A1 (en) | 2007-03-08 |
| CA2620085C (en) | 2016-07-12 |
| ZA200802490B (en) | 2009-10-28 |
| PA8693101A1 (es) | 2009-05-15 |
| AR055150A1 (es) | 2007-08-08 |
| EP1919892A2 (en) | 2008-05-14 |
| TW200745078A (en) | 2007-12-16 |
| JP2009506117A (ja) | 2009-02-12 |
| WO2007027527A3 (en) | 2007-05-24 |
| NO20081554L (no) | 2008-06-02 |
| US20070049618A1 (en) | 2007-03-01 |
| CA2899923A1 (en) | 2007-03-08 |
| DOP2006000193A (es) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008112221A (ru) | Соединения ряда изоиндолимидов, их композиции и способы применения | |
| JP2023501253A5 (https=) | ||
| RU2388750C2 (ru) | Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина | |
| JP2007519754A5 (https=) | ||
| RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
| RU2436776C2 (ru) | ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT | |
| RU2006134021A (ru) | Производные гетероарил-конденсированного пиразола | |
| JP4324791B2 (ja) | ２−アシルアミノチアゾール誘導体又はその塩 | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2017537948A5 (https=) | ||
| JP2004532227A5 (https=) | ||
| RU2005108999A (ru) | Азотсодержащие ароматические производные | |
| HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
| JP2006500348A5 (https=) | ||
| RU2009126624A (ru) | Производные 2-(пиперидин-4-ил)-4-фенокси-или фенилаинопиримидина в качестве ненуклеозидных ингибитров обратной транскриптазы | |
| RU2008135690A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| JP2017525757A5 (https=) | ||
| RU2011107437A (ru) | Ингибиторы кинуренин-3-моноксигеназы | |
| CA2471099A1 (en) | .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors | |
| JP2008517945A5 (https=) | ||
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| HRP20100284T1 (hr) | Derivati piperazinila korisni u liječenju bolesti posredovanih receptorom gpr38 | |
| JP2015227331A (ja) | ５−置換イソインドリン化合物 | |
| RU2003129502A (ru) | Соединение, фармацевтическая композиция, применение, способ предупреждения или лечения заболеваний | |
| RU2007132262A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20101012 |